BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 33281062)

  • 1. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
    Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
    Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases.
    Kowalski ES; Remick JS; Sun K; Alexander GS; Khairnar R; Morse E; Cherng HR; Berg LJ; Poirier Y; Lamichhane N; Becker S; Chen S; Molitoris JK; Kwok Y; Regine WF; Mishra MV
    Radiat Oncol; 2020 Oct; 15(1):245. PubMed ID: 33109224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
    Singh C; Qian JM; Yu JB; Chiang VL
    J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of multi-fraction stereotactic radiosurgery for surgically resected or intact large brain metastases from non-small-cell lung cancer (NSCLC).
    Minniti G; Scaringi C; Lanzetta G; Anzellini D; Bianciardi F; Tolu B; Morace R; Romano A; Osti M; Gentile P; Paolini S
    Lung Cancer; 2019 Jun; 132():119-125. PubMed ID: 31097084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
    Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
    Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
    BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic radiosurgery with immunotherapy is associated with improved overall survival in patients with metastatic melanoma or non-small cell lung cancer: a National Cancer Database analysis.
    Jiang JM; Kabarriti R; Brodin NP; Ohri N; Guha C; Kalnicki S; Garg M
    Clin Transl Oncol; 2022 Jan; 24(1):104-111. PubMed ID: 34236616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis.
    Yomo S; Oda K; Oguchi K
    J Neurosurg; 2023 Dec; 139(6):1628-1637. PubMed ID: 37243558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S; Komiya T; Powell E
    Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database.
    Kroeze SGC; Schaule J; Fritz C; Kaul D; Blanck O; Kahl KH; Roeder F; Siva S; Verhoeff JJC; Adebahr S; Schymalla MM; Glatzer M; Szuecs M; Geier M; Skazikis G; Sackerer I; Lohaus F; Eckert F; Guckenberger M
    Radiat Oncol; 2021 Jan; 16(1):4. PubMed ID: 33407611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
    Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
    Front Immunol; 2022; 13():875488. PubMed ID: 35693805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases.
    Cabanie C; Biau J; Durando X; Mansard S; Molnar I; Chassin V; Verrelle P; Khalil T; Lapeyre M; Dupic G
    Cancer Radiother; 2021 Jul; 25(5):432-440. PubMed ID: 33836954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Mortality and Radiation Necrosis After Surgery With Postoperative Stereotactic Radiation in Patients With Multiple Brain Metastases.
    Bhave VM; Lamba N; Tjong MC; Aizer AA; Bi WL
    Neurosurgery; 2024 Jan; 94(1):117-128. PubMed ID: 37489905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in patients with non-small cell lung carcinoma and brain metastases: a Malaysian perspective.
    Tang WH; Alip A; Saad M; Phua VC; Chandran H; Tan YH; Tan YY; Kua VF; Wahid MI; Tho LM
    Asian Pac J Cancer Prev; 2015; 16(5):1901-6. PubMed ID: 25773842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases.
    Koenig JL; Shi S; Sborov K; Gensheimer MF; Li G; Nagpal S; Chang SD; Gibbs IC; Soltys SG; Pollom EL
    World Neurosurg; 2019 Jun; 126():e1399-e1411. PubMed ID: 30902777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697 patients.
    Lehrer EJ; Ahluwalia MS; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Fakhoury KR; Rusthoven CG; Mathieu D; Trudel C; Malouff TD; Ruiz-Garcia H; Bonney P; Hwang L; Yu C; Zada G; Patel S; Deibert CP; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Jones BM; Green S; Sheehan JP; Trifiletti DM
    J Neurosurg; 2023 May; 138(5):1178-1187. PubMed ID: 36115055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition.
    Le A; Mohammadi H; Mohammed T; Burney H; Zang Y; Frye D; Shiue K; Lautenschlaeger T; Miller J
    J Neurooncol; 2022 Jul; 158(3):481-488. PubMed ID: 35641840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.
    Le Rhun E; Wolpert F; Fialek M; Devos P; Andratschke N; Reyns N; Regli L; Dummer R; Mortier L; Weller M
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32747372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.